STING agonist-4

STING agonist-4 refers to a candidate molecule intended as an agonist of human STING (Stimulator of Interferon Genes), an endoplasmic reticulum membrane protein that serves as a cytosolic DNA sensor crucial for the induction of type I interferon responses in innate immunity. STING agonists as a class are under active development for immunotherapy, particularly in oncology, where they aim to enhance the antitumor immune response by activating STING, which leads to downstream TBK1/IRF3 signaling and type I IFN production, thus promoting immune-mediated tumor cell killing. Several STING agonists have entered clinical or preclinical evaluation, ranging from cyclic dinucleotide (CDN) analogs to non-CDN small molecules and antibody-drug conjugates. Known molecules in this class include MK-1454, CRD3874, IMSA101, among others. There is no evidence in the literature or clinical trial registries for a distinct drug candidate specifically named "STING agonist-4"; thus, it either represents a developmental code name, a placeholder, or a molecule referenced in limited or non-publicly disclosed contexts. If more precise structural, clinical, or sponsor information about "STING agonist-4" becomes available, its description should be updated accordingly[2][3][6].

Other names

diamidobenzimidazole-4diamidobenzimidazole4diamidobenzimidazole 4Compound 4Compound4Compound-4